What is the appropriate ordering and dosing of intravenous immunoglobulin for a 50‑kg female in myasthenia gravis crisis?

IVIG Ordering for Myasthenia Gravis Crisis in a 50kg Female

Order IVIG 2 g/kg (total 100 grams for this 50kg patient) divided over 5 consecutive days at 0.4 g/kg/day (20 grams daily), administered intravenously. 1, 2

Specific Ordering Instructions

Dose Calculation

• Total dose: 100 grams (2 g/kg × 50 kg) 1, 2
• Daily dose: 20 grams (0.4 g/kg/day × 50 kg for 5 days) 1, 2
• Using a 5% IVIG solution (50 mg/mL), this equals 400 mL daily 3

Infusion Protocol

• Initial infusion rate: 0.5 mL/kg/min (0.5 mg/kg/min) for the first 30 minutes 3
• Maintenance rate: Gradually increase to maximum 5 mL/kg/min (5 mg/kg/min) if tolerated 3
• For this 50kg patient: start at 25 mL/min, increase to maximum 250 mL/min if tolerated 3

Pre-Treatment Assessment (Critical)

• Cardiac function evaluation with echocardiogram before IVIG administration 2
• Fluid status assessment - patients with depressed cardiac function may require divided dosing 2
• Renal function baseline (BUN, creatinine) - monitor throughout treatment 2
• Pulmonary function testing with negative inspiratory force (NIF) and vital capacity (VC) 2

Concurrent Management in Crisis

Immediate Interventions

• Admit to ICU or step-down unit with capability for rapid intubation 2
• Corticosteroids: Methylprednisolone 1-2 mg/kg/day IV (50-100 mg daily for this patient) concurrently with IVIG 2
• Pyridostigmine 30-60 mg PO every 4-6 hours (maximum 120 mg four times daily), titrate based on response 2

Medications to AVOID

• Beta-blockers, IV magnesium, fluoroquinolones, aminoglycosides, and macrolide antibiotics - all can worsen myasthenia 2, 1

Monitoring During Treatment

Daily Assessments Required

• Neurological examination daily to assess treatment response 2, 1
• Pulmonary function testing (NIF and VC) at least daily, more frequently if respiratory compromise 2, 1
• Vital signs throughout each infusion - slow or stop if adverse reactions occur 3
• Renal function monitoring (creatinine, BUN, urine output) 2

Laboratory Monitoring

• Acetylcholine receptor (AChR) antibodies if not already confirmed 2
• CPK, aldolase, troponin to evaluate for concurrent myositis or myocarditis 2
• ECG and consider cardiac MRI if any cardiac symptoms or elevated troponin 2

Evidence Supporting This Approach

The 2 g/kg total dose divided over 5 days represents the standard evidence-based regimen for myasthenia gravis crisis. 1, 2 A landmark randomized controlled trial demonstrated clinically meaningful improvement in Quantitative Myasthenia Gravis Score at day 14 with this dosing, with greatest benefit in patients with more severe disease (QMG score >10.5). 4

While some older studies examined lower doses (1 g/kg), a randomized trial comparing 1 g/kg versus 2 g/kg showed a trend toward greater improvement with the higher dose, though not reaching statistical significance. 5 The ASCO guidelines for immune checkpoint inhibitor-related myasthenia gravis explicitly recommend 2 g/kg over 5 days for grade 3-4 toxicity, which parallels myasthenic crisis severity. 2

Alternative Considerations

If Cardiac Dysfunction Present

• Divide the dose: 1 g/kg daily over 2 days (50 grams on day 1,50 grams on day 2) rather than 5 days 2
• Administer diuretics concurrently and monitor closely for volume overload 2

If No Response After 5 Days

• Do NOT give a second course of IVIG - risk of volume overload and hemolytic anemia 2
• Consider plasmapheresis instead - 5 sessions over 5-7 days as alternative rescue therapy 2, 1
• Escalate to high-dose pulse steroids (methylprednisolone 10-30 mg/kg/day) if requiring multiple vasopressors 2

Common Pitfalls to Avoid

Do not administer plasmapheresis immediately after IVIG - it will remove the administered immunoglobulin, negating therapeutic benefit. 1 If plasmapheresis is chosen as primary therapy, IVIG should be given after the final exchange session, not before. 2

Do not use IVIG products containing sucrose in patients with renal insufficiency - increased risk of osmotic nephrosis. 3 Flebogamma 5% DIF contains sorbitol instead and is safer, but still requires renal monitoring. 3

Do not infuse too rapidly - start at the minimum rate and increase gradually only if tolerated to minimize risk of thrombosis, particularly in this patient population at risk for hyperviscosity. 3